Clinical Trials
10 trialsNCT05633667 2026-06-01
VELOCITY-Lung
Gilead Sciences
Phase 2 Active not recruiting
NCT04310007 2026-05-29
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06731907 2026-05-26
MK-3475-01G
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07258147 2026-05-05
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Sichuan University
Phase 2 Not yet recruiting
NCT04892953 2026-02-19
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07307443 2025-12-29
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT03345810 2023-06-15
DURATION
AIO-Studien-gGmbH
Phase 2 Completed
NCT02328105 2022-08-09
LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT02684461 2022-06-03
Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed